Key Points

- Brookfield Infrastructure Corp. offers a yield of 2.58%.
- Realty Income provides a yield of 0.83%.
- Pfizer has a yield of 0.64%.
- These companies offer high yields and consistent payout increases.
- Investors looking for steady passive income should consider these stocks.

Investors searching for reliable sources of passive income with consistent growth potential may want to look into three particular high-yield dividend stocks currently on the market. These companies, including Brookfield Infrastructure Corp., Realty Income, and Pfizer, stand out for their attractive combination of above-average yields and regular dividends increases over time.

Starting with Brookfield Infrastructure Corp., this company offers investors a solid yield of 2.58% on their investment. Known for its stable and diversified asset base, Brookfield Infrastructure has a track record of increasing its payouts to shareholders, making it an appealing option for those seeking long-term passive income.

Realty Income, another excellent choice for passive income seekers, boasts a current yield of 0.83%. As a real estate investment trust (REIT) specializing in commercial properties, Realty Income has established itself as a reliable source of steady income through its consistent dividend payments and periodic increases.

Finally, Pfizer, a leading pharmaceutical company, offers investors a dividend yield of 0.64%. Despite a slightly lower yield compared to the other two stocks, Pfizer's strong financial position, global presence, and history of raising its dividends make it a compelling investment for those looking to build a portfolio of high-yield dividend stocks.

Overall, these three high-yield dividend stocks – Brookfield Infrastructure Corp., Realty Income, and Pfizer – present an appealing opportunity for investors seeking to generate passive income over the long term. With their combination of attractive yields and consistent payout growth, these stocks have the potential to provide a reliable source of income for years to come. Consider adding these companies to your investment portfolio for a lifetime of passive income.

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

For more information:

Up/Down Rally

Price Distribution

Analyst Recommendations

Earning Price Impact Analysis

Seasonality